Syntekabio Collaborates with Global Compound Supplier Enamine on AI-Based Synthetic Drug Development

Syntekabio is collaborating on AI synthetic drug development and global market expansion through a strategic partnership with global compound company Enamine.

AI drug development specialist Syntekabio (CEO Jeong Jong-seon) announced on the morning of the 2nd that it signed a memorandum of understanding (MOU) with global compound company Enamine at the Daejeon Dungok AI Bio Supercomputer Center (ABS Center) for compound supply and synthesis, and AI-based drug development.

Under this agreement, Enamine will provide an extensive synthetic compound library, and Syntekabio plans to apply this compound library to its AI drug platform ‘DeepMatcher’ candidate discovery service to derive optimized lead compounds for drug development.

Additionally, they will conduct joint marketing related to AI synthetic drug discovery services to accelerate both companies’ entry into the global market.

Enamine, headquartered in Ukraine, is a leading global compound supplier that offers comprehensive services including compound supply, binding affinity testing, and in vitro efficacy verification services such as ADMET screening. Recently, it has expanded its global network by establishing branches in the United States, Germany, and Poland.

Through this agreement, Enamine will leverage its expertise in organic synthesis, custom compound production, and preclinical biology services to collaborate on drug optimization and lead compound discovery utilizing Syntekabio’s AI-based molecular design capabilities.

Meanwhile, Syntekabio is actively conducting biopharmaceutical research using NEO-ARS and Ab-ARS, in addition to the synthetic drug candidate discovery service using DeepMatcher. In particular, NEO-ARS, a personal and shared neoantigen prediction service, and Ab-ARS, a novel antibody discovery and optimization research service, have been introduced at several global conferences and are attracting attention from global potential clients.

Enamine’s Director of Business Development, Iaroslava Kos, stated, “We are pleased to collaborate with Syntekabio to apply Enamine’s extensive compound library to Syntekabio’s AI platform.” She added, “This partnership will accelerate the discovery of optimized lead compounds and enhance the efficiency and effectiveness of drug development. We expect to create meaningful achievements in the field of synthetic drug development by combining the strengths of both companies.”

Syntekabio’s Chief Operating Officer, Cho Hye-kyung, said, “Syntekabio’s main business model is providing synthetic drug candidate discovery services using DeepMatcher to domestic and international clients, so securing a compound library is the foundation for discovering excellent candidate compounds. Through this collaboration, reflecting the large-scale compound library provided by Enamine in DeepMatcher will enable us to offer enhanced AI drug services and strengthen our competitiveness in the global market.”